Categories: Market Research

ACE Inhibitors Market Growth Outlook Through 2024-2033

Overview and Scope
ACE inhibitors, also known as angiotensin-converting enzyme (ACE) inhibitors, refer to a type of medication used to treat and manage hypertension. They function by stopping the body’s enzyme from generating angiotensin II, a chemical that constricts blood vessels and raises blood pressure. Its basic function is to relax the veins and arteries to reduce blood pressure.

Sizing and Forecast
The ace inhibitors market size has grown steadily in recent years. It will grow from $6.9 billion in 2023 to $7.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to risen cardiovascular disease incidence, increased aging population, clinical effectiveness and safety profile, prevalence of diabetes, regulatory endorsement and guidelines.

The ace inhibitors market size is expected to see strong growth in the next few years. It will grow to $9 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to growing global burden of cardiovascular diseases, expanding hypertension treatment guidelines, advancements in combination therapies, focus on heart failure management, rising awareness and healthcare access. Major trends in the forecast period include focus on kidney protection, preference for renin-angiotensin system inhibitors, generic competition and pricing pressures, patient-centric approaches in healthcare, regulatory updates and safety considerations.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Segmentation & Regional Insights
The ace inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents
2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs
3) By Dosage Form: Oral Tablets, Oral Solutions
4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications
5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

North America was the largest region in the ACE inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=10671&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of hypertension disorders is expected to drive the growth of the ACE inhibitors market going forward. High blood pressure, medically known as hypertension, is a condition characterized by elevated pressure within the blood vessels. ACE inhibitors, also known as angiotensin-converting enzyme inhibitors, are a group of medications utilized to treat and control hypertension. These medications function by relaxing the blood vessels, resulting in a reduction in blood pressure and an improvement in blood flow. For instance, in March 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, approximately 1.28 billion adults between the ages of 30 and 79 were affected by hypertension worldwide, with a majority (two-thirds) residing in low- and middle-income nations. In the past 30 years, there has been an increase of 650 million people aged 30-79 who have hypertension. An estimated 46% of adults with hypertension are unaware of their condition, lacking a diagnosis. Over the last 30 years, the number of adults aged 30-79 who have hypertension has increased by 650 million. An estimated 46% of persons with hypertension are unaware of their condition since they are not diagnosed. Therefore, the increasing prevalence of hypertension disorders is driving the growth of the ACE inhibitors market.

Key Industry Players

Major companies operating in the ace inhibitors market report are Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, United Therapeutics Corporation, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Solvay Pharmaceuticals B.V., Endo International PLC, Otto Brandes GmbH, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline PLC, Cadila Healthcare Limited, AbbVie Inc., Mylan N.V., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca PLC, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

The ace inhibitors market report table of contents includes:

1. Executive Summary

2. ACE Inhibitors Market Characteristics

3. ACE Inhibitors Market Trends And Strategies

4. ACE Inhibitors Market – Macro Economic Scenario

5. Global ACE Inhibitors Market Size and Growth

.
.
.

31. Global ACE Inhibitors Market Competitive Benchmarking

32. Global ACE Inhibitors Market Competitive Dashboard

33. Key Mergers And Acquisitions In The ACE Inhibitors Market

34. ACE Inhibitors Market Future Outlook and Potential Analysis

35. Appendix